0001573202-17-000013.txt : 20171212
0001573202-17-000013.hdr.sgml : 20171212
20171212195419
ACCESSION NUMBER: 0001573202-17-000013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171209
FILED AS OF DATE: 20171212
DATE AS OF CHANGE: 20171212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MacFarlane Katie
CENTRAL INDEX KEY: 0001608535
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16467
FILM NUMBER: 171252847
MAIL ADDRESS:
STREET 1: 101 POOR FARM ROAD 3RD FLOOR
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RespireRx Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0000849636
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330303583
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
BUSINESS PHONE: (201) 444-4947
MAIL ADDRESS:
STREET 1: 126 VALLEY ROAD
STREET 2: SUITE C
CITY: GLEN ROCK
STATE: NJ
ZIP: 07452
FORMER COMPANY:
FORMER CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/
DATE OF NAME CHANGE: 19920703
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2017-12-09
0
0000849636
RespireRx Pharmaceuticals Inc.
RSPI
0001608535
MacFarlane Katie
C/O RESPIRERX PHARMACEUTICALS INC.
126 VALLEY ROAD, SUITE C
GLEN ROCK
NJ
07452
1
0
0
0
Common Stock Options (to purchase shares of Common Stock)
1.45
2017-12-09
4
J
0
38114
A
2022-12-09
Common Stock
38114
38114
D
Common Stock Options (to purchase shares of Common Stock)
2
2022-06-30
Common Stock
25000
25000
D
Common Stock Options (to purchase shares of Common Stock)
3.9
2022-01-18
Common Stock
25000
25000
D
Common Stock Options (to purchase shares of Common Stock)
7.3775
2021-03-31
Common Stock
30770
30770
D
Common Stock Options (to purchase shares of Common Stock)
6.396
2022-08-18
Common Stock
9231
9231
D
Common Stock Options (to purchase shares of Common Stock)
8.125
2022-06-30
Common Stock
6154
6154
D
On December 9, 2017, Ms. MacFarlane forgave all of the accrued but unpaid directors fees to which she was entitled as of September 30, 2017, an aggregate of $55,000. On that date, the Company granted to Ms. MacFarlane options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000. These Common Stock Options vested upon issuance.
These Common Stock Options vested upon issuance.
These Common Stock Options vested in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017, and are all currently vested.
The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested.
These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested.
The Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested.
/s/ Kathryn MacFarlane
2017-12-12